ABSTRACT
Background: To identify an association between
MacTel and OSA and whether OSA may result in increased disease progression.
Design: Matched case-control study and retrospective cohort analysis.
Participants: Fifty-seven patients with MacTel and 165 matched controls from the Busselton Health Study.
Methods: MacTel participants were matched based on age, gender and body mass index (BMI) (and where possible hypertension and diabetes) on a 3:1 ratio with controls from the Busselton Health Study. Participants undertook a sleep questionnaire using a previously validated questionnaire.
In a subset sleep apnoea severity was objectively measured via overnight ambulatory polygraphy (30 cases and 83 matched controls; ApneaLink device; ResMed, Sydney, Australia). In a retrospective analysis of the suspected MacTel cases we assessed whether major markers of OSA severity and MacTel progression were associated.
Main Outcome Measures: Apnoea Hypopnea Index along with key markers of MacTel progression.
INTRODUCTION
Idiopathic macular telangiectasia type 2 (MacTel) is an uncommon, progressive condition that usually affects both eyes. Patients generally present in the fifth to seventh decades of life, whilst prevalence estimates range from 0.00045% to 0.1%. 1, 2 It is characterized by loss of retinal transparency, hyperfluorescence on retinal angiography in the absence of macula oedema, superficial crystalline deposits, right-angled venules, reduction in macular pigment, foveal thinning and infrequently, subretinal neovascularization. [3] [4] [5] [6] The underlying cause of MacTel remains obscure and there are no known ways to prevent its progression.
Obstructive Sleep Apnoea (OSA) is characterized by the episodic collapse of the upper airway during sleep resulting in repeated apnoeic episodes with concomitant increases in arterial blood pressure and reductions in blood oxygen saturation levels. Early prevalence estimates for symptomatic OSA range from 2% to 4% of the male and 1-2% of the female population, 7 while the prevalence of asymptomatic, undiagnosed OSA has been estimated to be as high as 20%. 8 Several comorbidities, including an increased prevalence of hypertension, obesity and cardiovascular disease are common within the OSA population. [9] [10] [11] These comorbidities are also prevalent within the population with MacTel, however their association with MacTel is poorly understood. 12 Recent studies have explored potential relationships between OSA and other retinal disease, specifically diabetic retinopathy where OSA has been reported as an independent risk factor in the progression of diabetic retinopathy. [13] [14] [15] More broadly, OSA has been implicated as a risk factor in other ophthalmic conditions including glaucoma, nonarteritic anterior ischemic optic neuropathy, central serous chorioretinopathy and floppy eyelid syndrome. 16 Although the exact pathogenesis of MacTel remains unclear, it has been postulated that Müller cell dysfunction may play a critical role throughout the disease process. [17] [18] [19] As the primary glial cell of the mammalian retina, it has been proposed that Müller Cells may provide substrates to photoreceptors such as lactate, for their anaerobic metabolism. 20 In two separate clinicopathological reports of MacTel, a striking feature was a derangement of macular Müller cells. 19, 21 Also it is reported that the retina has the highest metabolic demand per gram of any organ in the body, 22 with the highest energy consumption occurring during darkness/sleep. 23 Coupled with this, the episodic obstructions of the airway experienced in OSA initiates a cascade of histochemical changes which ultimately alters ocular blood flow regulation. 15 Taken all of these factors together, OSA has the potential to place further stress on the already compromised photoreceptors resulting in accelerated progression of neuronal degeneration in patients with MacTel. We had two objectives in this study. The first was to build a case-control study to investigate whether there is an increased risk of OSA in patients with MacTel compared with carefully matched controls. The hypothesis is that sleep apnoea may be a risk factor for the development of MacTel. The second, in a 2-year retrospective cohort, was to ascertain whether sleep apnoea is associated with worse progression of disease. The second hypothesis is that sleep apnoea may accelerate disease progression in people who have already developed MacTel.
METHODS

Cases
The cases were recruited and studied during 2011-2012 at the Sydney Eye Hospital, a major public tertiary and quaternary referral centre. Participants were identified from those currently enrolled in the global, multicentre MacTel project (www. The cases were investigated in two phases. In the first stage, a questionnaire incorporating the Berlin Questionnaire 24 (BQ-a self-reported measure of sleep apnoea risk) and Epworth Sleepiness Scale 25 (ESS-a measure of the likelihood of falling asleep in common everyday situations), was disseminated and completed via post or face-to-face interactions for those with clinical appointments during the time of the study along with an appropriate medical history and anthropometric data.
In the second stage, a group of 30 patients seen sequentially in the research clinic as part of their annual review for the MacTel Natural History Observation Study who had completed the questionnaire were invited to undergo overnight sleep testing using the ApneaLink device (ResMed Ltd, Sydney, Australia).
The ApneaLink is a multichannel device which records the number of apnoeas/hypopneas events per hour of sleep. It utilizes the Apnoea Hypopnea Index (AHI) to grade the severity of sleepdisordered breathing. An apnoeic event was defined as a cessation of breathing >10 s whilst hypopnea was defined as a > 50% reduction in airflow coupled with a > 4% reduction in oxygen saturation levels (SpO 2 ). An AHI score of 0-5 is classified as within the normal range, 6-15 mild, 16-30 moderate and an AHI >30 indicative of severe sleep apnoea. The ApneaLink device is also capable of measuring the oxygen desaturation (SpO 2 ) levels during the recording period with normal saturation levels at sea-level around 96-97% with recordings not less than 90% considered mild, 80-89% moderate and < 80% considered a severe reduction. When compared with the gold standard for diagnosing OSA, polysomnography, ApneaLink has been found to be both sensitive and specific in quantifying apnoeas and hypopneas of varying severities associated with OSA. [26] [27] [28] [29] The results were graded using the integrated ApneaLink software.
Controls
The community of Busselton in Western Australia has been the focus of a long-standing and ongoing cross-sectional health study which includes assessment of OSA. [30] [31] [32] [33] 
Statistical analyses
Comparison methods of the two samples, including testing for homogeneity and equality of means, were performed using chi-square and two sample t-tests for the outcomes of the self-reported sleep questionnaire. Participants were classified as being positive for OSA based on an AHI of >5. Tests for a dependent relationship between particular observed variables were performed using chi-squared tests for independence. Observed differences were considered using analysis of variance. When assessing disease progression between those MacTel patients with and without significant elevations in AHI and/or ODI relied on the criterion of change in mean best corrected visual acuity (BCVA), change in central macular thickness (CMT) and change in Gass-Blodi disease classification over 24 months. Logistic models were fitted for the worst eye as determined by their BCVA. 
RESULTS
Seventy individuals enrolled in the MacTel Natural History Observation Study were identified as eligible and were contacted to participate in the first phase (Table 1 ). There were 13 non-responders, leaving 57 (80%) participants who completed the questionnaire. Based on sex, age, BMI, hypertension and diabetes, the Busselton Population and Medical Research Institute provided 165 matched controls. The MacTel participants and controls were very well-matched for sex, age and BMI (see Table 1 ). A somewhat higher proportion of the controls had hypertension and a somewhat lower proportion had diabetes.
The self-reported outcomes of the BQ were similar between the two groups, with 23 (40%) of the MacTel cohort and 49 (30%) of the control participants self-reporting a high risk for OSA (P > 0.05). The MacTel cohort reported an Epworth Sleepiness Score of 6.4 (SD 5.0) whilst these values were unavailable for the control group as it was not collected as part of the data collection process.
We were able to identify three case-matches for each of 27 MacTel patients, two participants were matched on a 1:1 basis and one participant was excluded from the analysis as the subject was unable to be case matched on the basis of BMI (40.3 kg/m 2 ). All control participants had completed the BQ along with overnight sleep analysis using the single channel ResMed ApneaLink. No oximetry values were available for the controls as this optional testing channel on the ApneaLink apparatus was not used as part of the Busselton data collection. (21) 19 (12) 5 (17) 10 (12) BMI, body mass index; M, male; SD, standard deviation.
The MacTel cohort had a mean AHI of 9.6 (SD 14.7) which was similar to the control cohort (9.7, SD 10.8, P = 0.95; Table 2 ). There was no significant difference in the distribution of MacTel and control participants within any objective or subjective measure of sleep apnoea presence or severity (see Tables 2 & 3) .
Sleep apnoea severity as quantified by the AHI was moderately positively correlated with the BMI in the cases (rho = 0.40, P = 0.03) but not significantly so in the controls (rho = 0.14, P = 0.21).
OSA was not associated with a more advanced stage of MacTel as classified by Gass and Blodi, Gass and Blodi 4 (see Table 3 ). No measure of MacTel progression was significantly different between patients with and without sleep apnoea by either definition of OSA (see Table 3 all P > 0.05).
The MacTel cohort also underwent assessment of oxygen saturation levels as part of their ApneaLink assessment. The mean baseline saturation level was 97.3% (AE 0.47) whilst the mean saturation levels through the analysis period dropped to 94.4% (AE 0.79) with participants, on average, experiencing 24.2 min (SD AE 20.5) throughout the analysis period with saturation levels below 90%. These values were not available for the controls provided by the Busselton Population Medical Research Institute but is comparable if not slightly better than the general population. 30 
DISCUSSION
Obstructive sleep apnoea was not found to be a risk factor for MacTel in this case-control study where we carefully matched for age, gender and most importantly BMI. We found that that there was a high prevalence of at least mild obstructive sleep apnoea in a cohort of patients with MacTel (48%), however this high prevalence was not significantly different when compared with appropriately matched controls (57%). Nor, after controlling for key confounders, was the presence of OSA significantly associated with common measures of disease progression (change in visual acuity, central retinal thickness and Gass-Blodi disease stage) over 2 years.
The baseline characteristics of the MacTel cohort in the present study were very similar to those reported by Clemons et al. from the larger, multicentre MacTel Natural History and Observational Study for which the MacTel participants are a part of. Therefore the 30 patient cohort that we studied appear to be reflective of the wider MacTel community.
The 48% prevalence of OSA (AHI > 5) in the MacTel cohort (Table 2 ) was higher than has generally been reported for the normal population, 7, 31 however with the advent of more sensitive diagnostic techniques for OSA it may be consistent with the current literature. 32 The MacTel cohort was notably well-matched with controls for age, sex, BMI and somewhat less well matched for hypertension and diabetic status. It is a strength of this study that we matched by design for these important prevalent confounders.
We found that patients with at least mild OSA (AHI > 5) did not have progression of their MacTel at a rate significantly greater than those MacTel patients where the OSA was within normal limits (AHI ≤ 5; Table 4 ). In the short-term follow-up period of 2 years we did not find any evidence different rates of progression of the disease (change in BCVA, change in CMT and change in Gass-Blodi stage) in patients with OSA compared with those without. As the progression of MacTel is generally slow, a link between the two may be apparent in larger, longer-term studies. ‡ ODI = number of time per hour oxygen saturation levels drop >3% from baseline. § SaO 2 peripheral capillary oxygen saturation levels. AHI, Apnoea/Hypopnea Index; ODI, Oxygen Desaturation Index.
The matched case-controlled design is a strength of this study as it allowed for the significant cofounders of age, sex, hypertension, diabetes and BMI to be controlled. Historically, other studies of this magnitude have relied on controls to be identified through literature. 24 This is the first study of its kind to investigate an association between MacTel and OSA. Although the results of this study suggests no apparent link in the short to medium term further investigations may be warranted due to the slow progressive nature of MacTel. New technologies based on adaptive optics may be able to be utilized in any future studies which may enable quantification of the stresses induced in photoreceptors through the episodic hypoxic event seen in patients with OSA.
There are some inherent weaknesses of the study. Firstly, the selection of cases and controls may be problematic as the cases come from a selected clinical population from an inner Sydney hospital whilst the controls come from a population-based study in a rural town in Western Australia meaning that whilst they are well matched on known comorbidities there may be other confounding factors such as ethnicity which were not controlled. In addition the asymptomatic nature of the MacTel in the early stages of the disease and the lack of ophthalmic assessment on the controls means we cannot be certain that within the matched control sample that MacTel was not present. Despite some time passing between the collection of data and reporting the ApneaLink has remained the gold standard in home testing of OSA giving validity to the current day.
This results of this study suggest that MacTel patients are at no significant elevated risk of sleep apnoea and therefore it appears unlikely that sleep apnoea causes MacTel in susceptible individuals. Those MacTel patients with OSA do not appear to be at greater risk of progression in the short to medium term. Further work may be warranted to assess how the effective management of OSA may benefit patients with MacTel over the long-term course of the disease. § Central Macular Thickness as measured by spectral domain OCT (optical coherence tomography). The change in BCVA and CMT was, retrospectively, evaluated over a 2-year period. ¶ Logistical regression models controlling for the confounders of age, sex, diabetes, hypertension and body mass index with penalized maximum likelihood estimates were applied to account for the separation in data. GB, Glass and Blodi; LogMAR BCVA, logarithm of minimum angle of resolution, best corrected visual acuity; CMT, central macular thickness.
